Share Price and Basic Stock Data
Last Updated: January 14, 2026, 9:04 pm
| PEG Ratio | 2.15 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Insecticides India Ltd operates in the agro-chemicals and pesticides sector, with its stock currently priced at ₹642 and a market capitalization of ₹1,865 Cr. The company has reported a consistent revenue growth trajectory, with sales increasing from ₹1,504 Cr in March 2022 to ₹1,801 Cr in March 2023, and projected to reach ₹2,002 Cr by March 2025. The trailing twelve months (TTM) sales stood at ₹2,051 Cr, indicating a robust demand for its products. Quarterly sales have also shown fluctuations, peaking at ₹696 Cr in September 2023 and showing a strong recovery from lower quarters. This growth is reflective of the company’s strategic positioning in the market and its ability to navigate challenges in the agricultural sector. The increase in sales is attributed to expanding market reach and an improved product portfolio, which positions Insecticides India Ltd favorably against its competitors in a growing industry.
Profitability and Efficiency Metrics
Insecticides India Ltd reported a net profit of ₹142 Cr, with a return on equity (ROE) of 13.3% and return on capital employed (ROCE) of 17.2%. The operating profit margin (OPM) stood at 13% for the latest reporting period, reflecting the company’s ability to manage costs effectively despite fluctuating sales. The company recorded operating profits of ₹219 Cr for the fiscal year 2025, up from ₹163 Cr in the previous year. However, the quarterly results reveal variability, with operating profit margins fluctuating between 3% and 14% over the past year. The interest coverage ratio (ICR) at an impressive 33.25x indicates strong earnings relative to interest obligations, highlighting the company’s operational efficiency. Such metrics suggest a solid profitability framework, although the variability in margins suggests areas for operational improvement.
Balance Sheet Strength and Financial Ratios
The balance sheet of Insecticides India Ltd reflects a healthy financial structure, with total assets amounting to ₹1,973 Cr and total borrowings at ₹242 Cr, resulting in a low total debt-to-equity ratio of 0.09. The company has reserves of ₹1,167 Cr, indicating a strong capacity for reinvestment and growth. The company’s current ratio stands at 1.83, suggesting good short-term liquidity, while the quick ratio at 0.69 indicates a reasonable buffer for immediate obligations. The price-to-book value (P/BV) ratio is at 1.59x, signifying that the market values the company at a premium to its book value. Furthermore, the cash earning retention ratio is at 96.55%, demonstrating a strong capacity to reinvest profits back into the business, which is crucial for sustainable growth. Overall, the financial ratios indicate a strong balance sheet with effective capital management.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Insecticides India Ltd reveals a stable ownership structure, with promoters holding 72.30% of the company. Institutional investors, including foreign institutional investors (FIIs) and domestic institutional investors (DIIs), hold 4.51% and 9.50%, respectively, indicating a moderate level of institutional interest. The public shareholding stands at 13.69%, which has seen a slight increase over the past year. The total number of shareholders is reported at 22,336, showing growing retail investor engagement. This distribution reflects a strong promoter commitment and investor confidence, although the relatively low institutional ownership may limit broader market interest. The consistency in promoter shareholding, alongside increasing public stake, suggests a positive outlook on governance and operational transparency, which are critical factors for long-term investment.
Outlook, Risks, and Final Insight
Insecticides India Ltd is positioned well for future growth, driven by its solid revenue trends and profitability metrics. However, risks include potential volatility in raw material prices and regulatory challenges in the agrochemicals sector, which could impact margins. Additionally, increasing competition may pressure pricing strategies. The company’s ability to innovate and adapt to changing market demands will be crucial. Should the company continue to leverage its operational efficiency and maintain strong cash flow, it could enhance shareholder value significantly. Conversely, if external factors such as policy changes or supply chain disruptions arise, they could adversely affect performance. Overall, Insecticides India Ltd presents a compelling investment opportunity, contingent on its management of operational challenges and market dynamics.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Epigral Ltd | 5,080 Cr. | 1,178 | 2,114/1,110 | 12.6 | 487 | 0.51 % | 24.9 % | 22.3 % | 10.0 |
| Dharmaj Crop Guard Ltd | 821 Cr. | 243 | 391/165 | 16.9 | 131 | 0.00 % | 12.0 % | 9.28 % | 10.0 |
| Bhaskar Agrochemicals Ltd | 55.2 Cr. | 106 | 149/56.6 | 9.90 | 40.0 | 0.00 % | 21.3 % | 24.7 % | 10.0 |
| Bhagiradha Chemicals & Industries Ltd | 2,931 Cr. | 226 | 331/198 | 111 | 54.9 | 0.06 % | 7.44 % | 4.91 % | 1.00 |
| Best Agrolife Ltd | 1,045 Cr. | 442 | 570/244 | 81.6 | 342 | 0.43 % | 12.9 % | 9.95 % | 10.0 |
| Industry Average | 10,928.05 Cr | 1,114.19 | 31.85 | 382.34 | 0.43% | 15.21% | 19.87% | 7.04 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 582 | 357 | 302 | 640 | 696 | 358 | 272 | 657 | 627 | 359 | 359 | 691 | 641 |
| Expenses | 514 | 333 | 330 | 594 | 614 | 332 | 263 | 585 | 537 | 331 | 331 | 607 | 556 |
| Operating Profit | 68 | 23 | -28 | 46 | 82 | 26 | 9 | 72 | 90 | 29 | 28 | 84 | 85 |
| OPM % | 12% | 7% | -9% | 7% | 12% | 7% | 3% | 11% | 14% | 8% | 8% | 12% | 13% |
| Other Income | 0 | 0 | 0 | 4 | -0 | 1 | 5 | 3 | 2 | 0 | 3 | 4 | 3 |
| Interest | 3 | 5 | 4 | 3 | 3 | 3 | 2 | 2 | 2 | 1 | 2 | 4 | 4 |
| Depreciation | 6 | 6 | 7 | 7 | 7 | 7 | 8 | 7 | 7 | 8 | 7 | 7 | 9 |
| Profit before tax | 60 | 12 | -39 | 39 | 72 | 17 | 4 | 66 | 82 | 20 | 22 | 77 | 74 |
| Tax % | 25% | 25% | -26% | 26% | 26% | 28% | -95% | 25% | 25% | 25% | 37% | 25% | 25% |
| Net Profit | 45 | 9 | -29 | 29 | 53 | 12 | 8 | 49 | 62 | 15 | 14 | 57 | 55 |
| EPS in Rs | 15.09 | 3.15 | -9.80 | 9.81 | 17.99 | 4.15 | 2.73 | 16.60 | 21.17 | 5.16 | 4.82 | 19.69 | 19.01 |
Last Updated: January 1, 2026, 6:46 am
Below is a detailed analysis of the quarterly data for Insecticides India Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 641.00 Cr.. The value appears to be declining and may need further review. It has decreased from 691.00 Cr. (Jun 2025) to 641.00 Cr., marking a decrease of 50.00 Cr..
- For Expenses, as of Sep 2025, the value is 556.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 607.00 Cr. (Jun 2025) to 556.00 Cr., marking a decrease of 51.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 85.00 Cr.. The value appears strong and on an upward trend. It has increased from 84.00 Cr. (Jun 2025) to 85.00 Cr., marking an increase of 1.00 Cr..
- For OPM %, as of Sep 2025, the value is 13.00%. The value appears strong and on an upward trend. It has increased from 12.00% (Jun 2025) to 13.00%, marking an increase of 1.00%.
- For Other Income, as of Sep 2025, the value is 3.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4.00 Cr. (Jun 2025) to 3.00 Cr., marking a decrease of 1.00 Cr..
- For Interest, as of Sep 2025, the value is 4.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 4.00 Cr..
- For Depreciation, as of Sep 2025, the value is 9.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 7.00 Cr. (Jun 2025) to 9.00 Cr., marking an increase of 2.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 74.00 Cr.. The value appears to be declining and may need further review. It has decreased from 77.00 Cr. (Jun 2025) to 74.00 Cr., marking a decrease of 3.00 Cr..
- For Tax %, as of Sep 2025, the value is 25.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 25.00%.
- For Net Profit, as of Sep 2025, the value is 55.00 Cr.. The value appears to be declining and may need further review. It has decreased from 57.00 Cr. (Jun 2025) to 55.00 Cr., marking a decrease of 2.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 19.01. The value appears to be declining and may need further review. It has decreased from 19.69 (Jun 2025) to 19.01, marking a decrease of 0.68.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:11 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 801 | 892 | 906 | 994 | 1,073 | 1,194 | 1,363 | 1,420 | 1,504 | 1,801 | 1,966 | 2,002 | 2,051 |
| Expenses | 719 | 781 | 815 | 880 | 925 | 1,006 | 1,207 | 1,268 | 1,333 | 1,679 | 1,803 | 1,783 | 1,825 |
| Operating Profit | 82 | 111 | 91 | 114 | 148 | 188 | 156 | 153 | 171 | 122 | 163 | 219 | 226 |
| OPM % | 10% | 12% | 10% | 11% | 14% | 16% | 11% | 11% | 11% | 7% | 8% | 11% | 11% |
| Other Income | 0 | 0 | 0 | 4 | 3 | 0 | 2 | -2 | 3 | 1 | 10 | 7 | 10 |
| Interest | 27 | 33 | 26 | 20 | 16 | 15 | 24 | 7 | 7 | 13 | 11 | 7 | 11 |
| Depreciation | 7 | 14 | 16 | 16 | 17 | 20 | 24 | 25 | 26 | 26 | 29 | 29 | 31 |
| Profit before tax | 49 | 64 | 50 | 82 | 118 | 153 | 110 | 119 | 141 | 84 | 133 | 190 | 193 |
| Tax % | 18% | 15% | 21% | 28% | 29% | 20% | 22% | 22% | 24% | 25% | 23% | 27% | |
| Net Profit | 40 | 55 | 39 | 59 | 84 | 122 | 86 | 93 | 107 | 63 | 103 | 140 | 142 |
| EPS in Rs | 14.01 | 19.24 | 12.67 | 19.16 | 27.09 | 39.49 | 27.75 | 30.14 | 36.16 | 21.28 | 34.67 | 48.03 | 48.68 |
| Dividend Payout % | 10% | 0% | 11% | 7% | 5% | 3% | 10% | 4% | 6% | 14% | 9% | 4% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 37.50% | -29.09% | 51.28% | 42.37% | 45.24% | -29.51% | 8.14% | 15.05% | -41.12% | 63.49% | 35.92% |
| Change in YoY Net Profit Growth (%) | 0.00% | -66.59% | 80.37% | -8.91% | 2.87% | -74.75% | 37.65% | 6.91% | -56.18% | 104.61% | -27.57% |
Insecticides India Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 8% |
| 3 Years: | 10% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 10% |
| 3 Years: | 9% |
| TTM: | 21% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 20% |
| 3 Years: | 8% |
| 1 Year: | -15% |
| Return on Equity | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 11% |
| 3 Years: | 10% |
| Last Year: | 13% |
Last Updated: September 5, 2025, 7:40 am
Balance Sheet
Last Updated: December 4, 2025, 1:26 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 21 | 21 | 21 | 21 | 21 | 21 | 20 | 30 | 30 | 29 | 29 |
| Reserves | 234 | 279 | 388 | 444 | 527 | 641 | 710 | 798 | 847 | 886 | 982 | 1,053 | 1,167 |
| Borrowings | 258 | 322 | 206 | 237 | 114 | 305 | 191 | 100 | 54 | 163 | 87 | 104 | 242 |
| Other Liabilities | 287 | 308 | 322 | 277 | 338 | 388 | 372 | 505 | 473 | 615 | 611 | 702 | 536 |
| Total Liabilities | 791 | 921 | 936 | 978 | 1,000 | 1,355 | 1,293 | 1,424 | 1,394 | 1,694 | 1,710 | 1,888 | 1,973 |
| Fixed Assets | 170 | 205 | 194 | 185 | 232 | 240 | 239 | 239 | 253 | 262 | 283 | 278 | 380 |
| CWIP | 54 | 38 | 51 | 58 | 17 | 19 | 39 | 59 | 91 | 123 | 141 | 161 | 81 |
| Investments | 11 | 11 | 11 | 11 | 16 | 12 | 10 | 12 | 13 | 15 | 19 | 26 | 29 |
| Other Assets | 556 | 667 | 680 | 725 | 735 | 1,084 | 1,004 | 1,115 | 1,037 | 1,293 | 1,267 | 1,422 | 1,483 |
| Total Assets | 791 | 921 | 936 | 978 | 1,000 | 1,355 | 1,293 | 1,424 | 1,394 | 1,694 | 1,710 | 1,888 | 1,973 |
Below is a detailed analysis of the balance sheet data for Insecticides India Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 29.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 29.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,167.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,053.00 Cr. (Mar 2025) to 1,167.00 Cr., marking an increase of 114.00 Cr..
- For Borrowings, as of Sep 2025, the value is 242.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 104.00 Cr. (Mar 2025) to 242.00 Cr., marking an increase of 138.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 536.00 Cr.. The value appears to be improving (decreasing). It has decreased from 702.00 Cr. (Mar 2025) to 536.00 Cr., marking a decrease of 166.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,973.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,888.00 Cr. (Mar 2025) to 1,973.00 Cr., marking an increase of 85.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 380.00 Cr.. The value appears strong and on an upward trend. It has increased from 278.00 Cr. (Mar 2025) to 380.00 Cr., marking an increase of 102.00 Cr..
- For CWIP, as of Sep 2025, the value is 81.00 Cr.. The value appears to be declining and may need further review. It has decreased from 161.00 Cr. (Mar 2025) to 81.00 Cr., marking a decrease of 80.00 Cr..
- For Investments, as of Sep 2025, the value is 29.00 Cr.. The value appears strong and on an upward trend. It has increased from 26.00 Cr. (Mar 2025) to 29.00 Cr., marking an increase of 3.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,483.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,422.00 Cr. (Mar 2025) to 1,483.00 Cr., marking an increase of 61.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,973.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,888.00 Cr. (Mar 2025) to 1,973.00 Cr., marking an increase of 85.00 Cr..
Notably, the Reserves (1,167.00 Cr.) exceed the Borrowings (242.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -176.00 | -211.00 | -115.00 | -123.00 | 34.00 | -117.00 | -35.00 | 53.00 | 117.00 | -41.00 | 76.00 | 115.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 58 | 68 | 84 | 78 | 80 | 75 | 86 | 65 | 70 | 60 | 55 | 70 |
| Inventory Days | 189 | 220 | 190 | 232 | 214 | 355 | 202 | 248 | 228 | 247 | 220 | 265 |
| Days Payable | 124 | 118 | 114 | 108 | 128 | 141 | 96 | 136 | 117 | 128 | 114 | 150 |
| Cash Conversion Cycle | 124 | 170 | 159 | 201 | 166 | 289 | 192 | 177 | 181 | 178 | 161 | 185 |
| Working Capital Days | 18 | 40 | 75 | 80 | 93 | 116 | 98 | 108 | 111 | 92 | 99 | 107 |
| ROCE % | 16% | 17% | 12% | 16% | 20% | 21% | 14% | 15% | 16% | 10% | 13% | 17% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Small Cap Fund | 2,636,351 | 0.5 | 190.87 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 48.38 | 34.59 | 21.36 | 54.17 | 45.43 |
| Diluted EPS (Rs.) | 48.38 | 34.59 | 21.36 | 54.17 | 45.43 |
| Cash EPS (Rs.) | 58.63 | 44.36 | 30.10 | 67.59 | 57.14 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 372.74 | 342.44 | 310.26 | 440.71 | 396.93 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 372.74 | 342.44 | 310.26 | 440.71 | 396.93 |
| Revenue From Operations / Share (Rs.) | 687.32 | 664.37 | 608.60 | 762.20 | 687.17 |
| PBDIT / Share (Rs.) | 78.43 | 58.12 | 41.61 | 88.16 | 77.44 |
| PBIT / Share (Rs.) | 68.41 | 48.24 | 32.79 | 74.80 | 65.51 |
| PBT / Share (Rs.) | 66.05 | 44.56 | 28.24 | 71.44 | 57.59 |
| Net Profit / Share (Rs.) | 48.61 | 34.48 | 21.28 | 54.24 | 45.21 |
| NP After MI And SOA / Share (Rs.) | 48.81 | 34.59 | 21.36 | 54.44 | 45.43 |
| PBDIT Margin (%) | 11.41 | 8.74 | 6.83 | 11.56 | 11.26 |
| PBIT Margin (%) | 9.95 | 7.26 | 5.38 | 9.81 | 9.53 |
| PBT Margin (%) | 9.60 | 6.70 | 4.64 | 9.37 | 8.38 |
| Net Profit Margin (%) | 7.07 | 5.18 | 3.49 | 7.11 | 6.57 |
| NP After MI And SOA Margin (%) | 7.10 | 5.20 | 3.50 | 7.14 | 6.61 |
| Return on Networth / Equity (%) | 13.09 | 10.09 | 6.88 | 12.35 | 11.44 |
| Return on Capital Employeed (%) | 17.76 | 13.50 | 10.35 | 16.61 | 16.09 |
| Return On Assets (%) | 7.48 | 5.97 | 3.72 | 7.69 | 6.58 |
| Long Term Debt / Equity (X) | 0.02 | 0.02 | 0.00 | 0.00 | 0.00 |
| Total Debt / Equity (X) | 0.09 | 0.08 | 0.17 | 0.05 | 0.11 |
| Asset Turnover Ratio (%) | 1.11 | 1.15 | 1.16 | 1.07 | 1.04 |
| Current Ratio (X) | 1.83 | 1.90 | 1.62 | 1.97 | 1.86 |
| Quick Ratio (X) | 0.69 | 0.67 | 0.48 | 0.73 | 0.72 |
| Inventory Turnover Ratio (X) | 2.36 | 1.60 | 1.88 | 1.61 | 1.77 |
| Dividend Payout Ratio (NP) (%) | 4.16 | 8.67 | 23.41 | 0.00 | 4.40 |
| Dividend Payout Ratio (CP) (%) | 3.45 | 6.74 | 16.56 | 0.00 | 3.48 |
| Earning Retention Ratio (%) | 95.84 | 91.33 | 76.59 | 0.00 | 95.60 |
| Cash Earning Retention Ratio (%) | 96.55 | 93.26 | 83.44 | 0.00 | 96.52 |
| Interest Coverage Ratio (X) | 33.25 | 15.80 | 9.16 | 26.22 | 24.06 |
| Interest Coverage Ratio (Post Tax) (X) | 21.61 | 10.37 | 5.68 | 17.13 | 16.51 |
| Enterprise Value (Cr.) | 1764.96 | 1468.53 | 1522.18 | 1224.20 | 990.06 |
| EV / Net Operating Revenue (X) | 0.88 | 0.74 | 0.84 | 0.81 | 0.69 |
| EV / EBITDA (X) | 7.73 | 8.54 | 12.36 | 7.04 | 6.19 |
| MarketCap / Net Operating Revenue (X) | 0.86 | 0.73 | 0.76 | 0.80 | 0.68 |
| Retention Ratios (%) | 95.83 | 91.32 | 76.58 | 0.00 | 95.59 |
| Price / BV (X) | 1.59 | 1.43 | 1.51 | 1.39 | 1.19 |
| Price / Net Operating Revenue (X) | 0.86 | 0.73 | 0.76 | 0.80 | 0.68 |
| EarningsYield | 0.08 | 0.07 | 0.04 | 0.08 | 0.09 |
After reviewing the key financial ratios for Insecticides India Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 48.38. This value is within the healthy range. It has increased from 34.59 (Mar 24) to 48.38, marking an increase of 13.79.
- For Diluted EPS (Rs.), as of Mar 25, the value is 48.38. This value is within the healthy range. It has increased from 34.59 (Mar 24) to 48.38, marking an increase of 13.79.
- For Cash EPS (Rs.), as of Mar 25, the value is 58.63. This value is within the healthy range. It has increased from 44.36 (Mar 24) to 58.63, marking an increase of 14.27.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 372.74. It has increased from 342.44 (Mar 24) to 372.74, marking an increase of 30.30.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 372.74. It has increased from 342.44 (Mar 24) to 372.74, marking an increase of 30.30.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 687.32. It has increased from 664.37 (Mar 24) to 687.32, marking an increase of 22.95.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 78.43. This value is within the healthy range. It has increased from 58.12 (Mar 24) to 78.43, marking an increase of 20.31.
- For PBIT / Share (Rs.), as of Mar 25, the value is 68.41. This value is within the healthy range. It has increased from 48.24 (Mar 24) to 68.41, marking an increase of 20.17.
- For PBT / Share (Rs.), as of Mar 25, the value is 66.05. This value is within the healthy range. It has increased from 44.56 (Mar 24) to 66.05, marking an increase of 21.49.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 48.61. This value is within the healthy range. It has increased from 34.48 (Mar 24) to 48.61, marking an increase of 14.13.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 48.81. This value is within the healthy range. It has increased from 34.59 (Mar 24) to 48.81, marking an increase of 14.22.
- For PBDIT Margin (%), as of Mar 25, the value is 11.41. This value is within the healthy range. It has increased from 8.74 (Mar 24) to 11.41, marking an increase of 2.67.
- For PBIT Margin (%), as of Mar 25, the value is 9.95. This value is below the healthy minimum of 10. It has increased from 7.26 (Mar 24) to 9.95, marking an increase of 2.69.
- For PBT Margin (%), as of Mar 25, the value is 9.60. This value is below the healthy minimum of 10. It has increased from 6.70 (Mar 24) to 9.60, marking an increase of 2.90.
- For Net Profit Margin (%), as of Mar 25, the value is 7.07. This value is within the healthy range. It has increased from 5.18 (Mar 24) to 7.07, marking an increase of 1.89.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 7.10. This value is below the healthy minimum of 8. It has increased from 5.20 (Mar 24) to 7.10, marking an increase of 1.90.
- For Return on Networth / Equity (%), as of Mar 25, the value is 13.09. This value is below the healthy minimum of 15. It has increased from 10.09 (Mar 24) to 13.09, marking an increase of 3.00.
- For Return on Capital Employeed (%), as of Mar 25, the value is 17.76. This value is within the healthy range. It has increased from 13.50 (Mar 24) to 17.76, marking an increase of 4.26.
- For Return On Assets (%), as of Mar 25, the value is 7.48. This value is within the healthy range. It has increased from 5.97 (Mar 24) to 7.48, marking an increase of 1.51.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.09. This value is within the healthy range. It has increased from 0.08 (Mar 24) to 0.09, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.11. It has decreased from 1.15 (Mar 24) to 1.11, marking a decrease of 0.04.
- For Current Ratio (X), as of Mar 25, the value is 1.83. This value is within the healthy range. It has decreased from 1.90 (Mar 24) to 1.83, marking a decrease of 0.07.
- For Quick Ratio (X), as of Mar 25, the value is 0.69. This value is below the healthy minimum of 1. It has increased from 0.67 (Mar 24) to 0.69, marking an increase of 0.02.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.36. This value is below the healthy minimum of 4. It has increased from 1.60 (Mar 24) to 2.36, marking an increase of 0.76.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 4.16. This value is below the healthy minimum of 20. It has decreased from 8.67 (Mar 24) to 4.16, marking a decrease of 4.51.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 3.45. This value is below the healthy minimum of 20. It has decreased from 6.74 (Mar 24) to 3.45, marking a decrease of 3.29.
- For Earning Retention Ratio (%), as of Mar 25, the value is 95.84. This value exceeds the healthy maximum of 70. It has increased from 91.33 (Mar 24) to 95.84, marking an increase of 4.51.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 96.55. This value exceeds the healthy maximum of 70. It has increased from 93.26 (Mar 24) to 96.55, marking an increase of 3.29.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 33.25. This value is within the healthy range. It has increased from 15.80 (Mar 24) to 33.25, marking an increase of 17.45.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 21.61. This value is within the healthy range. It has increased from 10.37 (Mar 24) to 21.61, marking an increase of 11.24.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,764.96. It has increased from 1,468.53 (Mar 24) to 1,764.96, marking an increase of 296.43.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.88. This value is below the healthy minimum of 1. It has increased from 0.74 (Mar 24) to 0.88, marking an increase of 0.14.
- For EV / EBITDA (X), as of Mar 25, the value is 7.73. This value is within the healthy range. It has decreased from 8.54 (Mar 24) to 7.73, marking a decrease of 0.81.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.86. This value is below the healthy minimum of 1. It has increased from 0.73 (Mar 24) to 0.86, marking an increase of 0.13.
- For Retention Ratios (%), as of Mar 25, the value is 95.83. This value exceeds the healthy maximum of 70. It has increased from 91.32 (Mar 24) to 95.83, marking an increase of 4.51.
- For Price / BV (X), as of Mar 25, the value is 1.59. This value is within the healthy range. It has increased from 1.43 (Mar 24) to 1.59, marking an increase of 0.16.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.86. This value is below the healthy minimum of 1. It has increased from 0.73 (Mar 24) to 0.86, marking an increase of 0.13.
- For EarningsYield, as of Mar 25, the value is 0.08. This value is below the healthy minimum of 5. It has increased from 0.07 (Mar 24) to 0.08, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Insecticides India Ltd:
- Net Profit Margin: 7.07%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 17.76% (Industry Average ROCE: 15.21%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 13.09% (Industry Average ROE: 19.87%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 21.61
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.69
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 13.2 (Industry average Stock P/E: 31.85)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.09
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 7.07%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Agro Chemicals/Pesticides | 401-402, Lusa Tower, Delhi Delhi 110033 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Hari Chand Aggarwal | Chairman & Wholetime Director |
| Mr. Rajesh Kumar Aggarwal | Managing Director |
| Mr. Nikunj Aggarwal | Whole Time Director |
| Mr. Anil Kumar Goyal | Whole Time Director |
| Ms. Praveen Gupta | Independent Director |
| Mr. Anil Kumar Bhatia | Independent Director |
| Mr. Shyam Lal Bansal | Independent Director |
| Mr. Supratim Bandyopadhay | Independent Director |
FAQ
What is the intrinsic value of Insecticides India Ltd?
Insecticides India Ltd's intrinsic value (as of 14 January 2026) is ₹579.03 which is 9.81% lower the current market price of ₹642.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹1,865 Cr. market cap, FY2025-2026 high/low of ₹1,098/532, reserves of ₹1,167 Cr, and liabilities of ₹1,973 Cr.
What is the Market Cap of Insecticides India Ltd?
The Market Cap of Insecticides India Ltd is 1,865 Cr..
What is the current Stock Price of Insecticides India Ltd as on 14 January 2026?
The current stock price of Insecticides India Ltd as on 14 January 2026 is ₹642.
What is the High / Low of Insecticides India Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Insecticides India Ltd stocks is ₹1,098/532.
What is the Stock P/E of Insecticides India Ltd?
The Stock P/E of Insecticides India Ltd is 13.2.
What is the Book Value of Insecticides India Ltd?
The Book Value of Insecticides India Ltd is 411.
What is the Dividend Yield of Insecticides India Ltd?
The Dividend Yield of Insecticides India Ltd is 0.31 %.
What is the ROCE of Insecticides India Ltd?
The ROCE of Insecticides India Ltd is 17.2 %.
What is the ROE of Insecticides India Ltd?
The ROE of Insecticides India Ltd is 13.3 %.
What is the Face Value of Insecticides India Ltd?
The Face Value of Insecticides India Ltd is 10.0.